Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

FDA Expands Olumiant Approval to Adolescents With Alopecia Areata

29 September 2026 · By · Wire by Fusion42

Published

29 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at dermatologyadvisor.com →

◆ Verified

Fusion42 · 29 September 2026 · Fusion42 review

The FDA has expanded approval of Olumiant (baricitinib) to treat adolescents aged 12 and older with severe alopecia areata, based on successful phase 3 trial results showing significant hair regrowth. The pediatric safety profile aligns with adult data.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 25 Sep 2026 and 29 Sep 2026.

◆ ◆ The Wire takeaway

You face a new competitive frontier as adolescent patients gain access to Olumiant for severe alopecia areata, presenting fresh market opportunities and patient demographics to engage with now.

◆ Coverage

4 sources · first reported 25 Sep 2026 · latest 29 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalalopecia-areatapediatric-treatmentbaricitinibdermatology